Replies to post #214628 on Amarin Corp Plc (AMRN)

[Whalatane]

Atom. thx for the link .

First I need to find out if this is simply my Cardiologists view ...or if its Kaisers view .

My Cardiologist had stated in an earlier email dated 12/12/2018 ...that they may consider VASCEPA but only for secondary prevention ...ie documented MI, stented etc ....but not as per the new NLA statement " for diagnosed ASCVD with TG's over 135 on optimal statin therapy "

I need to find a way to really challenge Kaiser on this .
Anyone with any experience in advocating for patients ?
thx
Kiwi

[jfmcrr]

Is this what you're looking for?

Quote:
Adverse events (AE) occurring in ≥5% of VASCEPA patients and statistically more frequently with VASCEPA than placebo:

Well, that sure smooths the way for my suggestions. Ignoring this makes him look like he's fact resistant if not fact proof.